234 related articles for article (PubMed ID: 25193892)
21. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
[TBL] [Abstract][Full Text] [Related]
22. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
23. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
24. Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients.
Yamamoto M; Matsumoto T; Ohmori H; Takemoto M; Ikeda M; Sumimoto R; Kobayashi T; Kato A; Ohdan H
BMC Nephrol; 2021 Jun; 22(1):221. PubMed ID: 34126941
[TBL] [Abstract][Full Text] [Related]
25. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
[TBL] [Abstract][Full Text] [Related]
26. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients--A Pilot Investigation.
Teatini U; Liebchen A; Nilsson LG; Beck W; Longhena GR
Blood Purif; 2016; 41(1-3):80-6. PubMed ID: 26536083
[TBL] [Abstract][Full Text] [Related]
27. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Costa E; Swinkels DW; Laarakkers CM; Rocha-Pereira P; Rocha S; Reis F; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Acta Haematol; 2009; 122(4):226-9. PubMed ID: 19887781
[No Abstract] [Full Text] [Related]
28. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats.
Theurl M; Nairz M; Schroll A; Sonnweber T; Asshoff M; Haschka D; Seifert M; Willenbacher W; Wilflingseder D; Posch W; Murphy AT; Witcher DR; Theurl I; Weiss G
Haematologica; 2014 Sep; 99(9):1516-24. PubMed ID: 24895335
[TBL] [Abstract][Full Text] [Related]
29. Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients.
Naito T; Shun M; Nishimura H; Gibo T; Tosaka M; Kawashima M; Ando A; Ogawa T; Sanaka T; Nitta K
Clin Exp Nephrol; 2021 Oct; 25(10):1111-1120. PubMed ID: 34106373
[TBL] [Abstract][Full Text] [Related]
30. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.
Takasawa K; Takaeda C; Maeda T; Ueda N
Nutrients; 2014 Dec; 7(1):103-18. PubMed ID: 25551249
[TBL] [Abstract][Full Text] [Related]
31. Association of hepcidin and anemia in early chronic kidney disease.
Sonkar SK; Singh NK; Sonkar GK; Pandey S; Bhosale V; Kumar A; Usman K
Saudi J Kidney Dis Transpl; 2019; 30(2):315-324. PubMed ID: 31031367
[TBL] [Abstract][Full Text] [Related]
32. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
33. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.
Steensma DP; Sasu BJ; Sloan JA; Tomita DK; Loprinzi CL
Blood; 2015 Jun; 125(23):3669-71. PubMed ID: 26045598
[No Abstract] [Full Text] [Related]
34. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
35. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients.
Touzot M; Lefebvre T; Roux A; Maheas C; Ridel C; Puy H; Karim Z
Nephrology (Carlton); 2019 Jul; 24(7):751-757. PubMed ID: 30175513
[TBL] [Abstract][Full Text] [Related]
36. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
37. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.
Peters HP; Rumjon A; Bansal SS; Laarakkers CM; van den Brand JA; Sarafidis P; Musto R; Malyszko J; Swinkels DW; Wetzels JF; Macdougall IC
Nephrol Dial Transplant; 2012 Oct; 27(10):3923-9. PubMed ID: 22815544
[TBL] [Abstract][Full Text] [Related]
38. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
39. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
40. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
